SULFONE AMIDE DERIVATIVE AS BCL-2-SELECTIVE APOPTOSIS INDUCING AGENT FOR TREATMENT OF CANCER AND IMMUNE DISEASE

• Main Authors: WILLIAM J MCCLELLAN, GERARD M SULLIVAN, ROBERT A MANTEI, STEVEN W ELMORE, TAO ZHI-FU, SONG XIAOHONG, LAURA HEXAMER, PARK CHEOL-MIN, AARON R KUNZER, LE WANG, LISA HASVOLD, XILU WANG, ANDREW M PETROS, CHANG H PARK, ANDREW J SOUERS, WENDT MICHAEL D, DING HONG, GARY T WANG, GEORGE A DOHERTY, MILAN BRUNCKO
• Format: Patent
• Language: English; Japanese
• Published: 16.07.2015
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

PROBLEM TO BE SOLVED: To provide a compound which inhibits activity of anti-apoptosis BcI-2 or BcI-xL protein, and a composition containing the compound for treatment of cancer.SOLUTION: There are provided a compound represented by a formula (I) which inhibits activity of anti-apoptosis BcI-2 or BcI-xL protein, where Ais N and the like, B, Dand Eare an alkoxy group and the like, Yis H and the like, and Zis a substituted phenyl group and the like, and a composition containing the compound for treatment of bladder cancer, brain tumor, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphoblast leukemia, follicular lymphoma, T cell- or B cell-originated lymphatic malignancy, melanoma, myelocytic leukemia, myeloma, oral cavity cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, or spleen cancer. 【課題】抗アポトーシスＢｃＩ−２又はＢｃＩ−ｘＬタンパク質の活性を阻害する化合物、及びこの化合物を含む、癌を治療するための組成物の提供。【解決手段】式（Ｉ）で表される、抗アポトーシスＢｃＩ−２又はＢｃＩ−ｘＬタンパク質の活性を阻害する化合物、及びこれを含む、膀胱癌、脳腫瘍、乳癌、骨髄癌、子宮頸癌、慢性リンパ球性白血病、結腸直腸癌、食道癌、肝細胞癌、リンパ芽球性白血病、濾胞性リンパ腫、Ｔ細胞もしくはＢ細胞由来のリンパ性悪性疾患、メラノーマ、骨髄性白血病、骨髄腫、口腔癌、卵巣癌、非小細胞肺癌、前立腺癌、小細胞肺癌又は脾臓癌を治療するための組成物。[Ａ１はＮ等；Ｂ１、Ｄ１及びＥ１はアルコキシ基等；Ｙ１はＨ等；Ｚ１は置換フェニル基等]【選択図】なし